Kurzfassung

Despite as yet limited clinical effectiveness, DC based immunotherapy remains a promising approach for the treatment of cancer, but requires further improvement of its immunostimulatory effectiveness. Potent antitumor immunity often depends on the induction of type 1 (TH1) immune responses. Therefore, we will combine different DC maturation stimuli that are known to induce TH1 immunity (anti-CD40, IL-12, IL-18), with the aim to trigger a TH1 driven anti-tumor cytotoxic T lymphocyte (CTL)...Despite as yet limited clinical effectiveness, DC based immunotherapy remains a promising approach for the treatment of cancer, but requires further improvement of its immunostimulatory effectiveness. Potent antitumor immunity often depends on the induction of type 1 (TH1) immune responses. Therefore, we will combine different DC maturation stimuli that are known to induce TH1 immunity (anti-CD40, IL-12, IL-18), with the aim to trigger a TH1 driven anti-tumor cytotoxic T lymphocyte (CTL) response. Therefore CTL will be cocultured with anti-CD40, IL-12, IL-18 matured DC and e.g. CTL proliferation, interleukin secretion and the cytotoxic potential of these cells will be analysed. Finally we want to inoculate anti-CD40, IL-12, IL-18 matured DC loaded with tumor specific antigen into tumor bearing mice and analyse the antitumoral effect of this vaccination strategy in vivo.» weiterlesen» einklappen